CoChat

Effectiveness of Seasonal Malaria Chemoprevention in Children under Ten Years of Age in Senegal: A Stepped-Wedge Cluster-Randomised Trial

Open access

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Seasonal Malaria Chemoprevention (SMC) with sulfadoxine-pyrimethamine (SP) plus amodiaquine (AQ), given each month during the transmission season, is recommended for children living in areas of the Sahel where malaria transmission is highly seasonal. The recommendation for SMC is currently limited to children under five years of age, but, in many areas of seasonal transmission, the burden in older children may justify extending this age limit. This study was done to determine the effectiveness of SMC in Senegalese children up to ten years of age. METHODS AND FINDINGS: SMC was introduced into three districts over three years in central Senegal using a stepped-wedge cluster-randomised design. A census of the population was undertaken and a surveillance system was established to record all deaths and to record all cases of malaria seen at health facilities. A pharmacovigilance system was put in place to detect adverse drug reactions. Fifty-four health posts were randomised. Nine started implementation of SMC in 2008, 18 in 2009, and a further 18 in 2010, with 9 remaining as controls. In the first year of implementation, SMC was delivered to children aged 3-59 months; the age range was then extended for the latter two years of the study to include children up to 10 years of age. Cluster sample surveys at the end of each transmission season were done to measure coverage of SMC and the prevalence of parasitaemia and anaemia, to monitor molecular markers of drug resistance, and to measure insecticide-treated net (ITN) use. Entomological monitoring and assessment of costs of delivery in each health post and of community attitudes to SMC were also undertaken. About 780,000 treatments were administered over three years. Coverage exceeded 80% each month. Mortality, the primary endpoint, was similar in SMC and control areas (4.6 and 4.5 per 1000 respectively in children under 5 years and 1.3 and 1.2 per 1000 in children 5-9 years of age; the overall mortality rate ratio [SMC: no SMC] was 0.90, 95% CI 0.68-1.2, p = 0.496). A reduction of 60% (95% CI 54%-64%, p < 0.001) in the incidence of malaria cases confirmed by a rapid diagnostic test (RDT) and a reduction of 69% (95% CI 65%-72%, p < 0.001) in the number of treatments for malaria (confirmed and unconfirmed) was observed in children. In areas where SMC was implemented, incidence of confirmed malaria in adults and in children too old to receive SMC was reduced by 26% (95% CI 18%-33%, p < 0.001) and the total number of treatments for malaria (confirmed and unconfirmed) in these older age groups was reduced by 29% (95% CI 21%-35%, p < 0.001). One hundred and twenty-three children were admitted to hospital with a diagnosis of severe malaria, with 64 in control areas and 59 in SMC areas, showing a reduction in the incidence rate of severe disease of 45% (95% CI 5%-68%, p = 0.031). Estimates of the reduction in the prevalence of parasitaemia at the end of the transmission season in SMC areas were 68% (95% CI 35%-85%) p = 0.002 in 2008, 84% (95% CI 58%-94%, p < 0.001) in 2009, and 30% (95% CI -130%-79%, p = 0.56) in 2010. SMC was well tolerated with no serious adverse reactions attributable to SMC drugs. Vomiting was the most commonly reported mild adverse event but was reported in less than 1% of treatments. The average cost of delivery was US$0.50 per child per month, but varied widely depending on the size of the health post. Limitations included the low rate of mortality, which limited our ability to detect an effect on this endpoint. CONCLUSIONS: SMC substantially reduced the incidence of outpatient cases of malaria and of severe malaria in children, but no difference in all-cause mortality was observed. Introduction of SMC was associated with an overall reduction in malaria incidence in untreated age groups. In many areas of Africa with seasonal malaria, there is a substantial burden in older children that could be prevented by SMC. SMC in older children is well tolerated and effective and can contribute to reducing malaria transmission. TRIAL REGISTRATION: ClinicalTrials.gov NCT00712374.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pmed.1002175

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Trial profile.
Fig 1 Trial profile.CC BY · PubMed Central
Fig 2 Stepped-wedge introduction of SMC in 45 health post areas over three years. The upper maps show the health district boundaries (the district of Fatick was subdivided in 2010 to create a new district of Niakhar); land cover and water bodies; and the location of villages and health facilities. In the lower maps, the polygons show the catchment areas of the 54 health posts (drawn as the convex hull of the village coordinates). # Each zone comprised nine health post areas. The nine health post areas in Zone 6 remained untreated. * In 2008, SMC was delivered to children aged 3–59 months; in other years, SMC was provided for children aged 3–119 months.
Fig 2 Stepped-wedge introduction of SMC in 45 health post areas over three years. The upper maps show the health district boundaries (the district of Fatick was subdivided in 2010 to create a new district of Niakhar); land cover and water bodies; and the location of villages and health facilities. In the lower maps, the polygons show the catchment areas of the 54 health posts (drawn as the convex hull of the village coordinates). # Each zone comprised nine health post areas. The nine health post areas in Zone 6 remained untreated. * In 2008, SMC was delivered to children aged 3–59 months; in other years, SMC was provided for children aged 3–119 months.CC BY · PubMed Central
Fig 3 The malaria incidence rate ratio after to before introduction of SMC is shown for five study zones (1–5) where SMC was introduced, and the control area (Zone 6) that remained without SMC. The y-axis is the rate ratio comparing the years 2010:2008. Rate ratios for each age group are shown.
Fig 3 The malaria incidence rate ratio after to before introduction of SMC is shown for five study zones (1–5) where SMC was introduced, and the control area (Zone 6) that remained without SMC. The y-axis is the rate ratio comparing the years 2010:2008. Rate ratios for each age group are shown.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 191

Metadata

Authors
Cissé, B., Ba, E. H., Sokhna, C., NDiaye, J. L., Gomis, J. F., Dial, Y., Pitt, C., NDiaye, M., Cairns, M., Faye, E., NDiaye, M., Lo, A., Tine, R., Faye, S., Faye, B., Sy, O., Konate, L., Kouevijdin, E., Flach, C., Faye, O., Trape, J.-F., Sutherland, C., Fall, F. B., Thior, P. M., Faye, O. K., Greenwood, B., Gaye, O., & Milligan, P.
Affiliations
  • London School of Hygiene & Tropical Medicine (GB)
  • Institut de Recherche pour le Développement (SN)
  • Cheikh Anta Diop University (SN)
Corresponding author
Milligan, Paul
Venue
PLoS Medicine
Published
2016-11-22
Volume
13
Issue
11
Pages
e1002175
ISSN
  • 1549-1277 (ISSN-L)
  • 1549-1676
OpenAlex
W2549904414
Cited by
191
References
10
Citations by year
2026: 23 · 2025: 21 · 2024: 22 · 2023: 15 · 2022: 24 · 2021: 25 · 2020: 23 · 2019: 10 · 2018: 17 · 2017: 9 · 2016: 2
FWCI
12.60
Type
journal article
Language
en
Open access
Locations
  • PLoS Medicine (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
  • Research Portal (King's College London) (submittedVersion, cc-by)
Funders
Bill and Melinda Gates Foundation (40099)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Travel-related health issues
  • Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
Keywords
seasonal malaria chemoprevention, sulfadoxine-pyrimethamine, amodiaquine, malaria mortality, parasitemia, anemia, drug resistance, insecticide-treated nets, adverse drug reactions, community attitudes, Senegal
MeSH terms
Amodiaquine, Antimalarials, Child, Child, Preschool, Drug Combinations, Humans, Infant, Malaria, Pyrimethamine, Seasons, Senegal, Sulfadoxine, Chemoprevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effectiveness of Seasonal Malaria Chemoprevention in Children under Ten Years of Age in Senegal: A Stepped-Wedge Cluster-Randomised Trial. https://app.cochat.ai/papers/10.1371/journal.pmed.1002175
The paper
Cissé, B., Ba, E. H., Sokhna, C., NDiaye, J. L., Gomis, J. F., Dial, Y., Pitt, C., NDiaye, M., Cairns, M., Faye, E., NDiaye, M., Lo, A., Tine, R., Faye, S., Faye, B., Sy, O., Konate, L., Kouevijdin, E., Flach, C., . . . Milligan, P. (2016). Effectiveness of Seasonal Malaria Chemoprevention in Children under Ten Years of Age in Senegal: A Stepped-Wedge Cluster-Randomised Trial. PLoS Medicine. https://doi.org/10.1371/journal.pmed.1002175

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.